Acamprosate calcium as augmentation therapy for anxiety disorders.
Thomas L Schwartz, Umar A Siddiqui, Shafi Raza, Anne Costello
Index: Ann. Pharmacother. 44 , 1930-2, (2010)
Full Text: HTML
Abstract
Glutamate is a major excitatory neurotransmitter, while γ-aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter in the central nervous system. This GABA-glutamate imbalance is thought to play a role in the development of anxiety. Acamprosate calcium is thought to restore this chemical imbalance in alcohol withdrawal.To examine acamprosate calcium as augmentation therapy for treatment of anxiety.This 8-week, open-label study was designed to evaluate patients with anxiety who were stable on current medications (selective serotonin-reuptake inhibitors and serotonin-norepinephrine-reuptake inhibitors) but still symptomatic. Acamprosate was dosed at 1998 mg/day. Assessments included the Hamilton Rating Scale for Anxiety (HAM-A) and the Hospital Anxiety and Depression Scale.Thirteen patients enrolled in the study and received study medication. Acamprosate reduced anxiety symptoms (mean HAM-A score reduction to 8.87 from a baseline of 20). Sixty-two percent of patients receiving acamprosate achieved remission (HAM-A score ≤ 7). Modal dose was 1998 mg/day (range 999-1998). The most commonly reported adverse events were nausea (n = 1), gastrointestinal upset (n = 1), and increased dream activity (n = 1).Acamprosate calcium may be effective augmentation therapy in patients with treatment-resistant anxiety.
Related Compounds
Related Articles:
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.
2015-01-01
[Sci. Rep. 5 , 7608, (2015)]
[Neuropsychopharmacology 39(11) , 2601-10, (2014)]
2009-01-01
[Arzneimittelforschung 59 , 631-4, (2009)]
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence Baser, O., et al.
[Am. J. Manag. Care 8 , S222-34, (2011)]